methyl 3-((4-iodophenyl)amino)-3-oxopropanoate | 658709-61-6

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酯及其衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-((4-iodophenyl)amino)-3-oxopropanoate
• 英文别名: methyl N-(4-iodophenyl)-3-oxopropionate；N-(4-iodo-phenyl)-malonamic acid methyl ester；methyl 3-(4-iodoanilino)-3-oxopropanoate
• CAS: 658709-61-6
• 化学式: C₁₀H₁₀INO₃
• 分子量: 319.099
• InChiKey: VMSDDOKBSSTEFY-UHFFFAOYSA-N

物化性质

• 沸点：
  435.0±30.0 °C(Predicted)
• 密度：
  1.762±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 3-((4-iodophenyl)amino)-3-oxopropanoate 在 甲醇 、 甲烷磺酸 、 四磷十氧化物 、 sodium hydroxide 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 2,4-dichloro-6-iodoquinoline
  参考文献：
  名称：

  Discovery, Synthesis, and Biological Evaluation of Thiazoloquin(az)olin(on)es as Potent CD38 Inhibitors

  摘要：

  A series of thiazoloquin(az)olinones were synthesized and found to have potent inhibitory activity against CD38. Several of these compounds were also shown to have good pharmacokinetic properties and demonstrated the ability to elevate NAD levels in plasma, liver, and muscle tissue. In particular, compound 78c was given to diet induced obese (DIO) C57Bl6 mice, elevating NAD > 5-fold in liver and >1.2-fold in muscle versus control animals at a 2 h time point. The compounds described herein possess the most potent CD38 inhibitory activity of any small molecules described in the literature to date. The inhibitors should allow for a more detailed assessment of how NAD elevation via CD38 inhibition affects physiology in NAD deficient states.

  DOI：

  10.1021/jm502009h
• 作为产物：
  描述：

  丙二酸甲酯酰氯 、 对碘苯胺 在 三乙胺 作用下， 以 乙酸乙酯 为溶剂， 反应 16.0h， 以99%的产率得到methyl 3-((4-iodophenyl)amino)-3-oxopropanoate
  参考文献：
  名称：

  [EN] 6,6-FUSED HETEROARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS
  [FR] DERIVES D'HETEROARYLES FUSIONNES EN 6,6 UTILISES COMME INHIBITEURS DE METALLOPROTEASES MATRICIELLES

  摘要：

  本发明提供了公式（I）或其药学上可接受的盐所定义的化合物，其中R?l，Q，Yl，Y2，Y3Y，R2a，R2b，R5¿和n如规范中所定义。本发明还提供了包含公式（I）化合物的制药组合物，并且提供了将公式（I）化合物用作基质金属蛋白酶抑制剂的用途。

  公开号：

  WO2004014388A1

文献信息

• 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20040043985A1

  公开（公告）日：2004-03-04

  This invention provides compounds defined by Formula I 1 or a pharmaceutically acceptable salt thereof, wherein R 1 , Q, Y 1 , Y 2 , Y 3 , R 2a , R 2b , R 5 , and n are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

  本发明提供了由公式I1定义的化合物或其药学上可接受的盐，其中R1、Q、Y1、Y2、Y3、R2a、R2b、R5和n如规范中所定义。本发明还提供了药学组合物，包括由规范中定义的公式I的化合物或其药学上可接受的盐以及药学上可接受的载体、稀释剂或赋形剂。本发明还提供了在动物体内抑制MMP-13酶的方法，包括向动物体内给予公式I的化合物或其药学上可接受的盐。本发明还提供了治疗由MMP-13酶介导的疾病的方法，包括向患者内给予公式I的化合物或其药学上可接受的盐，单独或在药学组合物中。本发明还提供了治疗心脏病、多发性硬化症、骨关节炎和类风湿性关节炎、除骨关节炎或类风湿性关节炎之外的关节炎、心力衰竭、炎性肠病、年龄相关性黄斑变性、慢性阻塞性肺病、哮喘、牙周疾病、银屑病、动脉粥样硬化和骨质疏松症的方法，包括向患者内给予公式I的化合物或其药学上可接受的盐，单独或在药学组合物中。本发明还提供了组合物，包括公式I的化合物或其药学上可接受的盐，以及规范中描述的另一种药学活性成分。
• Novel coumarin-3-(N-aryl)carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1
  作者：Natala Srinivasa Reddy、Kiranmai Gumireddy、Muralidhar R. Mallireddigari、Stephen C. Cosenza、Padmavathi Venkatapuram、Stanley C. Bell、E. Premkumar Reddy、M.V. Ramana Reddy

  DOI：10.1016/j.bmc.2005.02.051

  日期：2005.5

  A series of novel coumarin carboxamides were synthesized, and their tumor cell cytotoxic activity was investigated. These compounds specifically inhibited the growth of cancer cells that have a high level of ErbB-2 expression. Immunoprecipitation analysis of the cell lysates prepared from carboxamide treated cancer cells showed the inhibition of ErbB-2 phosphorylation suggesting the interaction of these compounds with ErbB-2 receptor. The down regulation of the kinase activity was further confirmed by performing in vitro kinase assay with recombinant ErbB-2 incubated with carboxamides. The inhibition of ErbB-2 phosphorylation correlated with down-regulation of ERK1 MAP kinase activation that is involved in proliferative signaling pathway. Furthermore, the cell-killing activity of many of these inhibitors is restricted to tumor cells with no demonstrable cytotoxicity against normal human fibroblasts suggesting that these compounds are tumor-specific. (c) 2005 Elsevier Ltd. All rights reserved.
• COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES
  申请人：ENCEFA

  公开号：EP3658586A1

  公开（公告）日：2020-06-03
• [EN] COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES<br/>[FR] COMPOSÉS SE LIANT DE MANIÈRE SPÉCIFIQUE À CD38 POUR UNE UTILISATION DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES ET INFLAMMATOIRES
  申请人：ENCEFA

  公开号：WO2019020643A1

  公开（公告）日：2019-01-31

  The present invention relates to a compound, which specifically binds to CD38, for use as a medicament in the prevention and/or treatment of a neurodegenerative disease and/or an inflammatory disease, by the opening of NAADP receptors Two Pore Channels TPC and/or TPC2, wherein said compound activates the opening of NAADP receptors Two Pore Channels TPC1 and/or TPC2.